Sotiburafusp alfa clinical trials
Also written HB0025.
How each study uses sotiburafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sotiburafusp alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Huabo Biopharm Co., Ltd. (3) · Shanghai Huaota Biopharmaceutical Co., Ltd. (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sotiburafusp alfa.
- Jan 2027A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCPhase 2 · Huabo Biopharm Co., Ltd.
Studies
Open first, then newest update. How each study uses sotiburafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial CancerRecruitingPhase 3Shanghai Huaota Biopharmaceutical Co., Ltd.NCT07902999Written as HB0025 Injection
- Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung CancerNot yet recruitingPhase 3Shanghai Huaota Biopharmaceutical Co., Ltd.NCT07383116Written as HB0025 Injection
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCEnrolling by invitationPhase 2Huabo Biopharm Co., Ltd.NCT07376629Written as HB0025 20 mg/kg plus nab-paclitaxel
- A Study of HB0025 Injection in Patients With Advanced Renal CancerRecruitingPhase 2Huabo Biopharm Co., Ltd.NCT06222125Written as HB0025
- A Study of Injection HB0025 in Patients With Advanced Solid TumorsStatus unknownPhase 1Huabo Biopharm Co., Ltd.NCT04678908Written as HB0025
Given beside what is tested · 1 — sotiburafusp alfa is usual care or a partner of the new treatment
Codes
What other systems call sotiburafusp alfa · ClinicalTrials.gg INT014588
- UNII (FDA) 34DTV38QW5SOTIBURAFUSP ALFAOne source FDA
- NCI Thesaurus C179665Sotiburafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 34DTV38QW5 | SOTIBURAFUSP ALFA | One source FDA |
| NCI Thesaurus | C179665 | Sotiburafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.